Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR.From December 2003 to August 2005, 572 pat ...

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) have a poor prognosis, particularly those whose disease has progressed on previous platinum ...

In addition, cetuximab-resistant cells manifested strong ... Using immunofluorescent staining, we found an accumulation of intracellular endocytic vesicles staining for EGFR in parental cells ...

Cetuximab led to improved OS ... Correlative analysis in this trial was performed with p16 staining as a surrogate for HPV association on a large subset of tissues from all subsites, although ...

Cetuximab is a monoclonal antibody that specifically ... either as the percentage of EGFR-positive tumor cells or as the maximal staining intensity per cell, did not correlate significantly ...

Cetuximab binds to EFGR to stop the downstream protein signalling that promotes cancer growth. Currently, it is licensed for use as a first-line drug in patients with advanced cancer as well as a ...

Cetuximab combined with chemotherapy significantly improves PFS and OS in mCRC patients, as confirmed by a meta-analysis of 25 studies. The study highlights cetuximab's efficacy, despite ...

The monoclonal antibody cetuximab (Erbitux) was more effective than a newer drug, the immune checkpoint inhibitor medicine durvalumab (Imfinzi), in fighting head-and-neck tumors, the trial found.

Cetuximab is a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR) which is present on the surface of some cancer cells. Cetuximab binds to the receptor, preventing ...